— Know what they know.
Not Investment Advice
Also trades as: NOVN.SW (SIX) · $vol 436M · NVSEF (OTC) · $vol 3M · NVS.TO (TSX) · $vol 0M

NVS NYSE

Novartis AG
1W: +2.4% 1M: +5.7% 3M: -3.8% YTD: +11.0% 1Y: +16.8% 3Y: +72.8% 5Y: +121.5%
$156.86
+3.05 (+1.98%)
After Hours: $154.97 (-1.89, -1.20%)
Weekly Expected Move ±3.4%
$141 $146 $151 $156 $162
NYSE · Healthcare · Drug Manufacturers - General · Tech Score Buy · Power 62 · $292.3B mcap · 1.83B float · 0.111% daily turnover · Short 46% of daily vol
Credit Risk of going bust: lower than 80% of companies Debt: 14.4% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $1.81 (down 99%), Novartis AG would be worth roughly what it owes.
Total debt $49.01B against a stock market value of $292.35B.
Distance to default 9.62 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $28.61B (short-term plus half of long-term), stock volatility 27.6%; Altman Z'' 2.30. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Cash Flow Trends

Operating Cash Flow
$19.2B +9.2% ▲
5Y CAGR: +7.1%
Capital Expenditures
$1.6B +59.2% ▲
5Y CAGR: -9.7%
Free Cash Flow
$17.7B +28.1% ▲
5Y CAGR: +9.8%
Dividends Paid
$7.9B -3.1% ▼
Buybacks
$9.3B -11.1% ▼
Net Change in Cash
-$24M +98.8% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income$22.9B$6.0B$8.6B$11.9B$14.1B
Depreciation & Amort.$5.6B$6.7B$8.3B$6.1B$5.4B
Stock-Based Comp.$700M$791M$865M$1.0B$0
Change in Working Capital-$73M-$796M-$369M-$706M-$3.1B
Other Non-Cash Items-$15.7B$359M-$3.4B-$2.4B$3.3B
Operating Cash Flow$15.1B$14.2B$14.5B$17.6B$19.2B
— Investing Activities —
Capital Expenditures-$1.1B-$916M-$1.1B-$1.4B-$3.9B
Acquisitions (Net)$20.5B-$864M-$3.6B-$3.8B-$3.0B
Investment Purchases-$16.6B-$34.8B-$747M-$3.6B-$305M
Investment Sales$2.7B$39.5B$11.6B$3.7B$2.2B
Other Investing-$1.3B-$1.4B-$624M-$2.4B$141M
Investing Cash Flow$4.2B$1.5B$5.6B-$7.5B-$4.9B
— Financing Activities —
Net Debt Issuance-$5.7B-$2.6B-$1.9B$4.4B$2.7B
Stock Repurchased-$3.1B-$10.7B-$8.7B-$8.3B-$9.3B
Dividends Paid-$7.4B-$7.5B-$7.3B-$7.6B-$7.9B
Other Financing-$169M$181M$3.6B-$177M-$578M
Financing Cash Flow-$16.3B-$20.6B-$14.3B-$11.7B-$14.9B
Net Change in Cash$2.7B-$4.9B$5.9B-$1.9B-$24M
Cash End of Period$12.4B$7.5B$13.4B$11.5B$11.4B
Free Cash Flow$12.5B$12.0B$11.7B$13.8B$17.7B

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms